INM
InMed Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · CA
$1.36
−2.16%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.40
From 52W high−44.72%
Volume10307.00
Market cap$7.47M
P/E (TTM)—
P/S (TTM)0.0x
Div yield—
Key dataSep 18, 2026
Open
$1.40
From 52W high
−44.72%
Volume
10307.00
Market cap
$7.47M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.5x
P/E (TTM)
—
RSI (14)
47.7
MomentumView details →
1D Return
−2.16%
YTD Return
+28.30%
SummaryUpdated Jun 1, 2026
InMed Pharmaceuticals Inc. (NASDAQ:INM) is a clinical-stage pharmaceutical company founded in 1981 and headquartered in Vancouver, Canada. Originally incorporated as Cannabis Technologies Inc., the company changed its name to InMed Pharmaceuticals in October 2014 and went public in May 2014. InMed focuses on developing cannabinoid-based therapies for rare diseases and has evolved from early-stage research into clinical trials, with its lead product candidate currently in Phase 2 clinical development for a rare skin condition.
Similar companies
Latest newsMore news →
InMed Pharmaceuticals Inc. received a NASDAQ notice dated September 16, 2026 for failing to comply with the minimum shareholders' equity requirement under Rule 5550(b)(1), and intends to submit a compliance plan by November 2, 2026.2d agoInMed Pharmaceuticals reported its financial results for the fiscal year ended June 30, 2026.11d ago